Relapsing Remitting Multiple Sclerosis clinical trials

Explore recruiting relapsing remitting multiple sclerosis clinical trials.

Recruiting relapsing remitting multiple sclerosis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsing Remitting Multiple Sclerosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis (NEXT-MS)

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

Belgium, Romania, Poland, Portugal, Netherlands, Denmark +11 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

TRIO: A prospective randomized Trial of non-inferiority comparing RItuximab versus Ocrelizumab in relapsing-remitting multiple sclerosis.

France

Phase III and phase IV (Integrated) EU CTIS Study details

An Open Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less than 18 Years for the Treatment of Relapsing Remitting Multiple Sclerosis, with Optional Open-Label Extension (105MS306)

Slovakia, Bulgaria, Hungary, Croatia, Czechia

Therapeutic confirmatory (Phase III) EU CTIS Study details

NO EVIDENCE OF DISEASE ACTIVITY AFTER AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN AGGRESSIVE MULTIPLE SCLEROSIS: THE NET-MS STUDY

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-Label, Parallel-Group Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Ocrelizumab in Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

Italy, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Relapsing Remitting Multiple Sclerosis trials by city

Relapsing Remitting Multiple Sclerosis in Toronto Relapsing Remitting Multiple Sclerosis in Vancouver Relapsing Remitting Multiple Sclerosis in Montreal Relapsing Remitting Multiple Sclerosis in Calgary Relapsing Remitting Multiple Sclerosis in Edmonton Relapsing Remitting Multiple Sclerosis in Ottawa Relapsing Remitting Multiple Sclerosis in Winnipeg Relapsing Remitting Multiple Sclerosis in Quebec City Relapsing Remitting Multiple Sclerosis in Hamilton Relapsing Remitting Multiple Sclerosis in Kitchener Relapsing Remitting Multiple Sclerosis in London Relapsing Remitting Multiple Sclerosis in Halifax Relapsing Remitting Multiple Sclerosis in New York Relapsing Remitting Multiple Sclerosis in Los Angeles Relapsing Remitting Multiple Sclerosis in Chicago Relapsing Remitting Multiple Sclerosis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease